We are focused on drug discovery at unprecedented speed and scale, with lower risk and higher certainty across multiple diseases in parallel. With data from hundreds of millions of experiments, we have mapped the effects of thousands of compounds on gene expression to discover new therapies. Our Drug-Gene Atlas maps molecular structure and drug action to the whole cell transcriptome, revealing therapeutic candidates that rebalance gene expression to treat disease. Our proprietary artificial intelligence modeling suite, Conductor AI, used our Drug-Gene Atlas to discover and predict the effects of new drugs at transcriptome scale.
| Website | https://www.transcriptabio.com/ |
| Employees | 21 (12 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology |
| Keywords | Drug Development, Drug Discovery, High Throughput Screening, Drug Design, Biotechnology, Pharmaceutical Research, Biotech, Precision Medicine, Therapeutics, Pharmaceutical, Life Sciences, Disease Research, Genomics, Big Data Analytics, Clinical Trials, Machine Learning, Experimental Data, Data Analysis |
| Competitors | Roche, Thermo Fisher Scientific, Agilent Technologies, Illumina, QIAGEN, Integrated DNA Technologies, 10x Genomics, Oxford Nanopore Technologies, PacBio, BGI Genomics +37 more (view full list) |
Looking for a particular Transcripta Bio employee's phone or email?
Christopher Moxham is the Founder of Transcripta Bio.
12 people are employed at Transcripta Bio.